cyrilzakka/clinical-trials huggingface dataset:
Impact of Raltegravir on the Viral Reservoirs

The objective of the antiretroviral treatment is to inhibit the viral replication, estimated(appreciated) by the measure of the viral plasmatic load(responsibility). In this inhibition of the viral replication usually joins an immune reconstruction \[ 1 \]. Nevertheless, a viro-immunological dissociation, i.e. an undetectable viral load(responsibility) and an absence of immune reconstruction, is regularly observed. It is now turned out that an undetectable viral load(responsibility) does not correspond to the total absence of viral replication and that it is possible to detect of the intracellular pro-viral DNA . Raltegravir ®, because of its mode of action(share) inhibiting the integration of the pro-viral DNA in the chromosomes of the infected cells(units) , could decrease the intracellular reservoir of monocyte-macrophages, improve the homeostasis, so optimizing the cooperation lymphocytes T - macrophages. Several experimental data suggest that the regression of the abnormalities of cellular interactions, and the rate of apoptose abnormally raised(abnormally brought up) by cells(units) T at the patients in viro-immunological dissociation, could be obtained .

This study aims at measuring the impact of Raltegravir ® on the viral reservoirs lymphocyte and monocyte, to quantify the expression of the molecules of costimulation, the source(spring) of intercellular interactions lymphocytes - monocytes, and to measure the rate of apoptose of the cells(units) T.

20 patients will be included and followed over a period of 12 months

Population of the essay

Criteria of inclusion:

Patients from 18 years to 60 years HIV + treated(handled):

* Patients presenting an undetectable viral load(responsibility) for at least 6 months and no more than year, by the use of a tritherapy containing 2 NUC + 1 IP.
* Patients presenting an immunosuppression "average" with a rate of T CD4 understood between 350 and 500 cells(units) by ml.
* Patients known for a perfect observance.

Criteria of not inclusion:

* Preliminary Use of an inhibitor of the integrase
* Patients presenting an opportunist infection and\\or an evolutionary cancer
* Patients benefiting from a treatment by IL-2, interferon-alpha, steroids or the other medicines known to modify the immunity.
* Pregnant Women

Eligibility Criteria:
Inclusion Criteria:

Patients from 18 years to 60 years HIV + treated(handled):

* Patients presenting an undetectable viral load(responsibility) for at least 6 months and no more than year, by the use of a tritherapy containing 2 NUC + 1 IP.
* Patients presenting an immunosuppression "average" with a rate of T CD4 understood between 350 and 500 cells(units) by ml.
* Patients known for a perfect observance.
* Exclusion Criteria:

Preliminary Use of an inhibitor of the integrase

* Patients presenting an opportunist infection and\\or an evolutionary cancer
* Patients benefiting from a treatment by IL-2, interferon-alpha, steroids or the other medicines known to modify the immunity.
* Pregnant Women
Clinical Evaluation of the Safety and Performance of Microwave Coagulation Using the HS1 Instrument

Clinical evaluation of the safety and performance of microwave coagulation using the HS1 Instrument for actual or potential non-variceal bleeding in the upper Gastrointestinal (GI) tract


Eligibility Criteria:
Inclusion Criteria:

* Patient or authorised representative able to comprehend and sign the Informed Consent form.
* Actual or potential non-variceal bleeding in the upper GI, including angiodysplasia or AVM malformations such as Dieulafoy's lesion with a Glasgow-Blatchford score of greater than 1

Exclusion Criteria:

* As stated in the contraindications in the HS1 IFU;
* Aged \<18 years of age
* Those described as vulnerable populations in EN ISO 14155;
* Patients with a known coagulopathy (congenital);
* Concurrent participation in another experimental intervention or drug study
* Unwilling or unable to provide informed consent.
* A patient whose Glasgow-Blatchford score is 1 or less
Clinical Results of Asqelio Trifocal Toric Diffractive Intraocular Lens

The goal of this observational prospective clinical study is to learn about the clinical outcomes three months after binocular implantation of Asqelio Trifocal Toric IOL in 30 patients submitted to cataract surgery following standard clinical practice. The main questions it aims to answer are: How rotationally stable is the lens after implantation and how effective is in the correction of refractive astigmatism.

Additionally, the visual performance at different distances will be assessed, as well as the patient-reported outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Patients submitted to cataract surgery with phacoemulsification with bilateral implantation of Asqelio Trifocal Toric IOL to avoid residual astigmatism
* Patient signing informed consent
* Clear intraocular media, except for cataracts in both eyes prior to surgery
* Monocular potential postoperative visual acuity of 20/25 or better

Exclusion Criteria:

* Corneal astigmatism lower than 0.75D
* Patients who do not provide informed consent
* Patients who do not understand the study procedure
* Previous corneal surgery or trauma
* Irregular cornea (e.g. keratoconus)
* Choroidal hemorrhage
* Microphtalmos
* Severe corneal dystrophy
* Uncontrolled or medically controlled glaucoma
* Clinically significant macular changes
* Concomitant severe eye disease
* Non-age-related cataract
* Severe optic nerve atrophy
* Diabetic retinopathy
* Proliferative diabetic retinopathy
* Amblyopia
* Extremely shallow anterior camera
* Severe chronic uveítis
* Pregnant or nursing
* Rubella
* Mature/dense cataract that makes it difficult to examine the fundus preoperatively.
* Previous retinal detachment
* Concurrent participation in other research with drugs or clinical devices
* Expect to require another eye surgery during the study period
Parity and Respiratory Muscle Strength in Women

The aim of this study is to investigate the relationship between parity and respiratory muscle strength in women.

In normal anatomical structure, there is myofascial continuity between the diaphragm, abdominal muscles and pelvic floor muscles. In addition to this anatomical unity, when the diaphragm muscle descends with inhalation, the pelvic floor muscle moves caudally, allowing breathing to encounter less resistance; the opposite occurs during exhalation.

Pregnancy and childbirth create anatomical and physiological changes in the female body. As a result of the growing uterus, the diaphragm moves upwards, while the pelvic floor muscles become depressed as intra-abdominal weight increases. On the other hand, it is thought that increased ligament laxity is responsible for changes in the body's muscle structure, especially in the lower body. Considering these pregnancy-related changes, the functions of these interrelated muscle groups may be affected and synergistic movements in the woman's body may be disrupted after pregnancy.

The aim of this study is to examine whether the anatomical structures affected during pregnancy have permanent effects on respiratory muscle strength and core muscles after birth. Volunteers who agree to participate in the study will be divided into groups according to their birth counts and respiratory and core muscles will be evaluated using objective methods.

Eligibility Criteria:
Inclusion Criteria:

* Being between 20-45 years old
* Being female

Exclusion Criteria:

* Having a body mass index of ≥30 kg/m2
* History of cardiovascular, neurological, pulmonary disease
* Being receiving active cancer treatment
* Having a history of lumbar surgery
* History of smoking
* Being a licensed athlete
Garlic With Lime Juice and Chlorhexidine Mouthwash

the study about herbal mouthwash. it is clinical trial .the investigator will compare between chlorhexidine mouthwash and garlic with lime juice mouthwash.and their effect on gingival bleeding and plaque and salivary bacteria.

the study about herbal mouth wash. it is clinical trial .the investigator will compare between chlorhexidine mouthwash and garlic with lime juice mouthwash.and show their effect on gingival bleeding and strepococcus bacteria present in saliva and plaque.

1. Preparation of garlic with lime juice will occur under aseptic condition.and give it to the first group.

   provide chlorhexidine to the second group.
2. Collection of plaque and saliva samples will be obtained from children who fulfilled the inclusion criteria.
3. Asses gingival condition by asking patient.
4. Subjects will be instructed to rinse for 14 days, twice daily.
5. Morning after breakfast and night before going to bed.
6. With 10 ml (undiluted) of the assigned mouthwash for 30 s and then expectorate the rinse.
7. Again after 14 days, the saliva and plaque samples will be taken and inoculated on blood agar plates to determine the colony count and the gingival index by loe and illness will be assessed.

Eligibility Criteria:
Inclusion criteria:

1. Children aged between 9 and 12 years.
2. Children are having normal occlusion (no crowding), non-compromised oral health (brushed their teeth once-daily) using toothbrush and non-fluoridated toothpaste. And practicing no other oral hygiene measures.
3. Medically free history.
4. Absence of orthodontic appliances.

Exclusion criteria:

1. History of current or recent (at least for the past 1 month) antibiotic usage or other medications.
2. Presence of Abscess, draining sinus, cellulitis, or other conditions requiring emergency dental treatment.
3. not willing to comply with the study.
Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy

Very few factors may be identified as prognostic for patients with bladder cancer undergoing radical cystectomy. Recently, detection of circulating tumor cells has shown to be very promising in anticipating both the likelyhood of distant metastases and survival in patients with breast cancer, melanoma, prostate cancer and other malignancies. In the present study we both tested the detection rate of circulating tumor cells using a PCR based methodology in the peripheral blood of patients undergoing radical cystectomy, and we further correlated our results with their clinical outcome.


Eligibility Criteria:
Inclusion Criteria:

* Prior trans urethral resection of the bladder (TUR)
* Histological confirmation of a transitional cell carcinoma (TCC) of the bladder
* ECOG Performance Status ≤ 2
* WBC count ≥4,000/μL; platelet count ≥150,000/μL; creatinine ≤1.8 mg/dL; AST, ALT, and alkaline phosphatase ≤2X the upper limit of normal, normal total bilirubin
* recent (within 6 weeks of cystectomy) total body CT imaging study excluding distant metastases as well as upper urinary tract TCC

Exclusion Criteria:

* Neo-adjuvant chemotherapy (either planned or already performed)
* Patients receiving investigational medications
* Subjects not suitable for a radical cystectomy
* Patients not willing to participate
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease

This project will determine the feasibility and efficacy of remote assessment and treatment of balance disorders in people with Parkinson's disease.

This project consists of a virtual balance assessment which will use objective measures of balance and gait obtained with wearable sensors on the feet and waist. During a virtual assessment, the Modified Instrumented Stand and Walk Test (ISAW) will be conducted in 80 people with Parkinson's disease (PD) to predict a gold-standard, clinical in-person assessment of balance, the Mini-Balance Evaluation System Test (Mini-BESTest). For the balance rehabilitation there will be 80 participants randomized into two groups: 1) unsupervised home Agility Boot Camp (ABC) exercises (standard of care), 2) telerehabilitation with therapist conducting the ABC exercise program. Mobility during daily life will be measured using wearable sensors to explore if improvements after rehabilitation transfer to daily life mobility. The long-term goal of this project is to develop a more effective, home-based balance assessment and treatment that can be used in older adults with balance impairments to improve safe mobility during daily life.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of idiopathic PD from movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia and one or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions
2. responsive to levodopa (self-reported)
3. Hoehn \& Yahr stages I-III;
4. ages 55-85 years old
5. ability to follow directions in order to participate in testing procedures and exercise classes
6. free of any medical conditions or medication that contraindicates participation in an exercise program
7. willing and able to participate in rehabilitation intervention approximately 3x/week for 4 weeks while also refraining from making changes to medications (as reasonable) or to other exercise programs during the study period.

Exclusion Criteria:

1. Major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than PD, significantly affecting gait and balance (i.e., musculoskeletal disorder, vestibular problem, head injury, stroke, cardiac disease, etc.)
2. no medical condition that precludes exercise
3. cognitive inability to participate in an exercise program, such as MoCA score less than or equal to 19, prior diagnosis of dementia or inability to follow directions
4. recurrent fallers, defined as those who fall more than 3 times a week (from patient and caregiver recollection)
5. excessive use of alcohol or recreational drugs
6. recent change in medication
7. inability to stand and walk for ISAW without an assistive device.
Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more than 48 weeks(+8 weeks).

The study will start after investigator determines the administration of Olomax tablets based on the investigator's judgement and obtaining informed consent from the subject during subject's daily visit.

The dose of the Olomax tablet for each subject will be determined based on efficacy and drug resistance according to the subject's previous drug administration.

Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more than 48 weeks(+8 weeks).

Efficacy of Olomax tablets will be evaluated based on the data collected from more than 24 weeks to 48 weeks(+8 weeks) from the baseline visit. Safety of Olomax tablets will be evaluated based on the adverse events collected during the study peroid.

Eligibility Criteria:
Inclusion Criteria:

1. Adults over the age of 19
2. Patients eligible for Olomax Tab. prescription in accordance with the approved product manual in Korea
3. Patients who are determined to prescribe Olomax Tab. at the discretion of the investigators.

   * Antihypertensive agent: Do not include more than 3 agents.
   * Anti-abnormal lipidemia: Do not include more than 2 agents.
   * Subjects who are already administered beta blocker (BB) or diuretics due to other diseases such as angina, not for the purpose of treating hypertension may be included.
4. Consent on the use of information by the patient

Exclusion Criteria:

1. Patients who have already administered olomax tablets.
2. Subject who fall under ' Do not administer to the following patients' in the precautions for use
3. A patient who does not meet the inclusion/exclusion criteria participates
4. The patient withdraws consent for the study
5. The administration of the study drug is discontinued
6. It is impossible to follow up during the observation period
7. The investigator determines that it is no longer feasible to continue the study
High Intensity and Moderate Training and Maximal Oxygen Uptake and Activity Levels

Aim of the study is to investigate the effect of different types of training (high intensity and moderate training) on maximal oxygen uptake and activity levels in an elderly Norwegian population after one year training intervention. Baseline data include the activity levels assessed through self reported means as well as objectively measured activity data using activity monitors.


Eligibility Criteria:
Inclusion Criteria:

* ability to walk at least 1km,
* born in 1938,1939,1940,1941 or 1942
* Sufficiently good health to be able to take part in the study, as determined by the researchers

Exclusion Criteria:

* Illness or disability that precludes exercise or hinders completion of the study
* Uncontrolled hypertension
* Symptomatic valve disease, hyper tropic cardio-myopathy or unstable angina
* Active cancer
* Test results indicating that study participation is unsafe
* Inclusion in other studies conflicting with participation in this one
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

An Open-label, Phase 2 study of efficacy and tolerability of ABT-869 in advanced hepatocellular carcinoma (HCC)

Eligibility Criteria:
Inclusion Criteria

* Subject must be greater than or equal to 18 years of age
* Subject must be diagnosed with unresectable or metastatic HCC
* Subjects must have a measurable lesion by RECIST on CT scan in at least one site which has not received radiation
* Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2
* No other active malignancy within the past 5 years

Exclusion Criteria

* Subject has received targeted VEGF/PDGF/TKI therapy. Prior Avastin is allowed
* Subject has Child-Pugh grade Class C hepatic impairment
* The subject has proteinuria Common Toxicity Criteria (CTC) grade \> 1 as measured by routine urinalysis or 24 hour urine collection during screening assessment
* Subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention
* The subject has a documented left ventricular Ejection Fraction \< 50%
* Subject is receiving therapeutic anticoagulation therapy
Postoperative Quality of Life in Treated Patients With Human Adjuvant Disease

This study aims to describe the quality of life in patients submitted to surgical excision of the adjuvants and injured surrounding tissue. For this purpose, the EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life. Although there are only five domains, it has been found to cover the most critical dimensions of quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of human adjuvant disease due to foreign substances injection
* Treated surgically to remove foreign substance
* In a private practice setting and treated all by plastic surgeon senior author.

Exclusion Criteria:

* History of antidepressant use during the follow up
Radiological Classification of the Facial Nerve

Cortical mastoidectomy and posterior tympanotomy is a classic approach for cochlear implant. Intimate knowledge of the relevant surgical anatomy of the temporal bone and facial recess is important to safely perform the posterior tympanotomy. Anatomical variation of facial nerve such as lateral or anterior position of vertical segment of facial nerve, will render this approach challenging. In this research, investigators proposed a Radiological Classification system of the position of vertical segment of facial nerve in relation to the lateral semicircular canal to predict difficult cases with narrow facial recess.

Cochlear implantation done by mastoidectomy, posterior tympanotomy and round window membrane insertion or cochleostomy, if we have to. In cases with very laterally placed vertical segment of the facial nerve a trans- mastoid trans- attic approach used with trans canal monitoring as an alternative approach. Position of the vertical segment of the facial nerve (VFN) determined by coronal view HRCT of temporal bone, bone window of 0.6 mm thickness by using the cut posterior to the internal auditory canal at the level of lateral semicircular canal (LSCC) and then drawing a line parallel to the bony canal of the VFN and another parallel line on the outer bony wall of lateral semicircular canal (LSCC), and comparing level of both. The location of the facial nerve classified into normal if the FN is medial, same level or lateral to LSCC . Investigators referred the laterally placed FN (LPFN) when the whole vertical segment of facial nerve is lateral to LSCC. In addition, distance between VFN and LSCC was measured in cases of laterally placed FN.

Investigators proposed a radiological classification system of the mastoid segment of facial nerve to predict round window niche accessibility through posterior tympanotomy pre-operatively by using coronal view computed tomography scan of temporal bone. Facial nerve position classified into 3 types in relation to LSCC:

1. TYPE I Medial to LSCC
2. TYPE II Same level of LSCC
3. TYPE III Laterally placed to LSCC III a) Less than 2mm III b) More than 2mm

Eligibility Criteria:
Inclusion Criteria:

* All patient who underwent cochlear implant surgery with preoperative computed tomography scan and high resolution CT scan of temporal bone

Exclusion Criteria:

* None
Randomized Controlled Trial Comparing Transanal Doppler-guided Arterial Ligation With Mucopexy and Stapled Haemorrhoidopexy

This multicentre RCT aims to compare two surgical treatments of haemorrhoidal disease: doppler-guided arterial ligation with mucopexy (DGALM) and stapled haemorrhoidopexy according to Longo (SH). The hypothesis of the trial is that the DGALM is at a lesser risk and is more cost-effective than SH. With a large number of patients managed in more than 20 centres, we aim to demonstrate that DGALM has a lower morbidity than SH when treating haemorrhoidal disease. At a lower postoperative risk and a lower risk of sequelae, the DGALM would demonstrate to be cost-effective for health care system and attractive for patients.


Eligibility Criteria:
Inclusion Criteria:

* Patient (male or female) 18 - 75 y.o
* Suffering from symptomatic grade II or III haemorrhoidal disease (bleeding and/or prolapse)
* requiring surgery

Exclusion Criteria:

* Acute complication of haemorrhoidal disease
* History of anal surgery for haemorrhoids
* Congenital or acquirred anal stenosis
* Anal fissure or perianal abcess
* Inflammatory bowel disease
* Colon or rectal cancerv History of rectal or sigmoid resection
* Rectal prolapse
* Portal vein hypertension
* Haemophylia
* Pregnancy